Improving the Efficiency and Efficacy of Glibenclamide in Limiting Progressive Hemorrhagic Necrosis Following Traumatic Spinal Cord Injury
Abstract
Preclinical work has demonstrated that glibenclamide administration improves outcomes in rat models of spinal cord injury, with the principal mechanism of action being amelioration of post-traumatic hemorrhagic necrosis (PHN). We hypothesize that some but not all patients with spinal cord injury, principally those with incomplete lesions, will respond to glibenclamide therapy. Our goal is identify early markers of injury that can be used to predict which patients may benefit from glibenclamide treatment. In this proposal, we will measure early biological markers of injury severity, specifically, serum biomarkers and T2 MRI findings obtained within hours of injury. We will subsequently correlate these early abnormalities with 6-month neurological examinations. During the first year of this grant, the notice of award was received on February 23, 2011, and the first patient was enrolled 5/29/11. As of the time of this report, we have screened 18 patients of which 6 patients have been enrolled. Another important development is that we recently broadened entry criteria to include additional patients with incomplete lesions, specifically those with central cord syndrome. This minor change is expected to significantly increase enrollment of patients with incomplete lesions.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2011
- Accession Number
- ADA554969
Entities
People
- J. M. Simard
Organizations
- University of Maryland, Baltimore